î
îŒ
î
Takeda Pharmaceutical Co Ltd
TAK16.310USD
-0.060-0.37%
çµå€Â 01/09, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
51.53Bæ䟡ç·é¡
228.91çŽè¿12ã¶æPER
î
詳现æ å ± Takeda Pharmaceutical Co Ltd äŒæ¥å
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltdã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãTAK
äŒç€ŸåTakeda Pharmaceutical Co Ltd
äžå Žæ¥Jun 21, 2085
æé«çµå¶è²¬ä»»è
ãCEOãWeber (Christophe)
åŸæ¥å¡æ°47455
蚌åžçš®é¡Depository Receipt
決ç®ææ«Jun 21
æ¬ç€Ÿæåšå°4F
éœåžCHUO-KU
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœJapan
éµäŸ¿çªå·103-8668
é»è©±çªå·81332782111
ãŠã§ããµã€ãhttps://www.takeda.com/
äŒæ¥ã³ãŒãTAK
äžå Žæ¥Jun 21, 2085
æé«çµå¶è²¬ä»»è
ãCEOãWeber (Christophe)
Takeda Pharmaceutical Co Ltdã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Jean-Luc Butel
Mr. Jean-Luc Butel
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Mr. Tokumasa Takeda
Mr. Tokumasa Takeda
Global Finance Chief Accounting Officer & Corporate Controller
Global Finance Chief Accounting Officer & Corporate Controller
--
--
Mr. Michel Orsinger
Mr. Michel Orsinger
Independent Director
Independent Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
--
--
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
ä»ã®
72.06B
6.48%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
545.17B
48.99%
Europe And Canada (Country)
272.90B
24.52%
Japan
111.06B
9.98%
Latin America
60.92B
5.47%
China (Country)
49.45B
4.44%
ä»ã®
73.28B
6.59%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Gastrointestinal diseases
353.49B
31.77%
Plasma derivatives
256.53B
23.05%
Rare diseases
184.12B
16.55%
Oncology
149.03B
13.39%
Neuroscience
97.55B
8.77%
ä»ã®
72.06B
6.48%
æ ªäž»
æŽæ°æå»: Mon, Nov 17
æŽæ°æå»: Mon, Nov 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
ä»ã®
98.94%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
ä»ã®
98.94%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
1.85%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.32%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
ä»ã®
97.26%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
596
85.43M
2.70%
-773.11K
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Capital Research Global Investors
13.40M
0.42%
+108.56K
+0.82%
Sep 30, 2025
Parametric Portfolio Associates LLC
6.05M
0.19%
+74.59K
+1.25%
Sep 30, 2025
UBS Financial Services, Inc.
5.86M
0.19%
+1.88M
+47.19%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.17M
0.13%
+85.28K
+2.09%
Sep 30, 2025
Brandes Investment Partners, L.P.
3.93M
0.12%
+219.53K
+5.91%
Sep 30, 2025
Renaissance Technologies LLC
3.86M
0.12%
+565.40K
+17.14%
Sep 30, 2025
Goldman Sachs Asset Management, L.P.
3.33M
0.11%
+481.85K
+16.91%
Sep 30, 2025
Aperio Group, LLC
3.31M
0.1%
+100.83K
+3.15%
Sep 30, 2025
TD Securities, Inc.
3.00M
0.1%
+3.00M
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
2.83M
0.09%
+1.61M
+132.12%
Sep 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
VanEck Pharmaceutical ETF
5.05%
SGI Enhanced Global Income ETF
0.76%
Adasina Social Justice All Cap Global ETF
0.49%
First Trust Value Line Dividend Index Fund
0.38%
ActivePassive International Equity ETF
0.3%
Avantis Responsible International Equity ETF
0.09%
Avantis International Equity ETF
0.05%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
詳现ãèŠã
VanEck Pharmaceutical ETF
æ¯ç5.05%
SGI Enhanced Global Income ETF
æ¯ç0.76%
Adasina Social Justice All Cap Global ETF
æ¯ç0.49%
First Trust Value Line Dividend Index Fund
æ¯ç0.38%
ActivePassive International Equity ETF
æ¯ç0.3%
Avantis Responsible International Equity ETF
æ¯ç0.09%
Avantis International Equity ETF
æ¯ç0.05%
Roundhill GLP-1 & Weight Loss ETF
æ¯ç0%
DFA Dimensional International Core Equity 2 ETF
æ¯ç0%
Invesco Zacks Multi-Asset Income ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
1.44T
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Sep 08, 2025
TAK.NB Final Cash Dividend of gross USD 0.322144 paid on Dec 11, 2025 going ex on Sep 30, 2025
Sep 30, 2025
Dec 11, 2025
Sep 30, 2025
Mar 04, 2025
TAK.NB Approximate interim Cash Dividend of gross USD 0.33901 paid on Jul 07, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Jul 07, 2025
Mar 31, 2025
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Takeda Pharmaceutical Co Ltdã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îTakeda Pharmaceutical Co Ltdã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Capital Research Global Investorsã¯13.40Mæ ªãä¿æããŠãããããã¯å šäœã®0.42%ã«çžåœããŸãã
Parametric Portfolio Associates LLCã¯6.05Mæ ªãä¿æããŠãããããã¯å šäœã®0.19%ã«çžåœããŸãã
UBS Financial Services, Inc.ã¯5.86Mæ ªãä¿æããŠãããããã¯å šäœã®0.19%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯4.17Mæ ªãä¿æããŠãããããã¯å šäœã®0.13%ã«çžåœããŸãã
Brandes Investment Partners, L.P.ã¯3.93Mæ ªãä¿æããŠãããããã¯å šäœã®0.12%ã«çžåœããŸãã
Capital Research Global Investorsã¯13.40Mæ ªãä¿æããŠãããããã¯å šäœã®0.42%ã«çžåœããŸãã
Parametric Portfolio Associates LLCã¯6.05Mæ ªãä¿æããŠãããããã¯å šäœã®0.19%ã«çžåœããŸãã
UBS Financial Services, Inc.ã¯5.86Mæ ªãä¿æããŠãããããã¯å šäœã®0.19%ã«çžåœããŸãã
Fidelity Management & Research Company LLCã¯4.17Mæ ªãä¿æããŠãããããã¯å šäœã®0.13%ã«çžåœããŸãã
Brandes Investment Partners, L.P.ã¯3.93Mæ ªãä¿æããŠãããããã¯å šäœã®0.12%ã«çžåœããŸãã
Takeda Pharmaceutical Co Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îTakeda Pharmaceutical Co Ltdã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.
Takeda Pharmaceutical Co LtdïŒTAKïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q4æç¹ã§ãTakeda Pharmaceutical Co Ltdã®æ ªåŒãä¿æããŠããæ©é¢ã¯596瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ85.43Mã§ãå
šäœã®2.70%ãå ããŠããŸãã2025Q3ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯0.21%å¢å ããŠããŸãã
Takeda Pharmaceutical Co Ltdã®æ倧ã®åçæºã¯äœã§ããïŒ
îFY2026Q2ã«ãããŠãGastrointestinal diseaseséšéãTakeda Pharmaceutical Co Ltdã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯353.49Bã§ãå
šåçã®31.77%ãå ããŠããŸãã
